Medical News

RSS

New vaccine strategy to advance solutions for tuberculosis

Against a backdrop of growing concern about the impact of tuberculosis on children, top scientific experts today published a global plan of action for developing the vaccines that are seen as critical to eliminating the disease. Published today in a special issue of the journal, Tuberculosis , the strategic blueprint for the TB vaccine field, represents consensus reached by the TB vaccine community.

20 Mar 2012

Sharp rise recorded in cases of new strain of whooping cough: New genotype may be evading vaccine’s protective effects

Australia’s prolonged whooping cough epidemic has entered a disturbing new phase, with a study showing a new strain or genotype may be responsible for the sharp rise in the number of cases.

20 Mar 2012

Feeding babies on demand improves their IQ: Study

A new study shows that who are fed when they are hungry – with breast milk or formula – achieve higher scores in Sats tests at ages five, seven, 11 and 14, and that by the age of eight they have an IQ four to five points higher. However, mothers who keep to scheduled feeding times score better on wellbeing measures, and report feeling more confident and less tearful.

20 Mar 2012

Obesity gene mutation identified in mice

A new study has found why a mutation in a particular gene can lead to obesity. Mouse experiments suggested the body's message to “stop eating” was blocked if the animals had the mutation. The study, published in Nature Medicine, said the brain's response to appetite hormones was being disrupted.

20 Mar 2012

Indian patent court licenses generic copy of Bayer’s blockbuster anticancer drug

Last week an Indian patent court shocked the $600 billion global pharmaceutical business by ordering Bayer, the German health care giant, to allow a tiny Indian generic drug company to sell cheap copies of the blockbuster cancer drug Nexavar – even though everyone agrees that the drug is protected by a patent. Instead, the court decided that Bayer had an obligation to make Nexavar available to people in India who needed it.

20 Mar 2012

Synthetic marijuana use among teenagers raises concerns

According to reports three U.S. teenagers ended up in the emergency department with altered mental states and seriously elevated heart rates after smoking synthetic marijuana.

20 Mar 2012

Electroconvulsive therapy and how it works in severe depression: Study

Electroconvulsive therapy, or ECT, has been used in severely and persistently depressed patients from their disabling mood state for more than seven decades. Researchers have searched for the reason why this technique sometimes works in these patients.

20 Mar 2012

“Meth” babies more at risk of behavioral problems: Study

A new study shows methamphetamine's potential lasting behavioral effects on kids of mothers who used meth during pregnancy. The behavior differences — anxiety, depression, moodiness — weren't huge, but lead researcher Linda LaGasse called them “very worrisome.”

20 Mar 2012

Court rules in favor of graphic labels on cigarette packages

An appeals court ruled on Monday that the government’s planned graphic warnings on cigarette packages was legal and didn’t violate the free speech rights of tobacco companies.

20 Mar 2012

Mylan receives final FDA approval for generic Boniva ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ibandronate Sodium Tablets, 150mg.

20 Mar 2012

PROLOR commences hGH-CTP Phase II trial in children with GHD

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in children with growth hormone deficiency.

20 Mar 2012

Acelrx fourth quarter net loss increases to $6.4 million

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2011.

20 Mar 2012

First Edition: March 20, 2012

Today's headlines include reports about the new GOP budget proposal, to be unveiled today by House Budget Committee Chairman Paul Ryan, R-Wis.

20 Mar 2012

Delcath receives first commercial order for CHEMOSAT system from IEO

Delcath Systems, Inc. announced today that it has received the first commercial order for the Company's Hepatic CHEMOSAT Delivery System from the European Institute of Oncology (Instituto Europeo di Oncologia – IEO) –a premier cancer treatment and research center in Europe.

20 Mar 2012

Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.

20 Mar 2012

Ampio receives U.S. patent allowance for lead drug Ampion

Ampio Pharmaceuticals, Inc., a biopharmaceutical company conducting clinical trials on its three lead drugs, licensing distribution of these drugs and engaged in further drug development, today announced that it has received notice of allowance from the US Patent Office of an additional patent that complements and expands its anti inflammatory patent portfolio for its lead drug Ampion.

20 Mar 2012

n3D releases new 24-well Bio-Assembler

Only days after Rainbow BioSciences closed a deal to acquire an equity interest in Nano3D Biosciences, n3D announced the release of its groundbreaking new 24-well Bio-Assembler.

20 Mar 2012

RaySearch receives PMH contract for new adaptive radiation therapy solution

RaySearch Laboratories AB has been awarded a contract for a new adaptive radiation therapy solution at Princess Margaret Hospital (PMH) in Toronto, Canada. This means that RaySearch will deliver its treatment planning system RayStation to PMH where it will be used as the primary treatment planning tool for adaptive radiation therapy.

20 Mar 2012

Pediatricians' unconscious racial bias may affect pain medication decisions

Pediatricians who show an unconscious preference for European Americans tend to prescribe better pain-management for white patients than they do for African-American patients, new University of Washington research shows.

20 Mar 2012

Study identifies function of GlialCAM gene in brain edema

A study of the pathophysiology of this rare disease has uncovered one mechanism that destabilizes the homeostatic balance of brain cells causing edema.

20 Mar 2012